Cell Therapy With Mesenquimial Stem Cells Of Bone Marrow Improves Renal Function In Pre-Clinical Module

Acute kidney injury (AKI) is a disease characterized by a drop in glomerular filtration rate and is considered a public health problem because it causes morbidity and mortality. In some cases, cell therapy with mesenchymal stem cells (MSC) may be an option for resumption of kidney function and resting. Thus, the present study evaluated the effects of cell therapy with bone marrow-derived MSC on acute renal injury in male Wistar rats exposed to the chemotherapeutic agent cisplatin. The animals were divided into 4 experimental groups (n = 06): Bone marrow donor group (DG); Control Group (CG) - animals treated with PBS and not receiving MSC transplantation; Nephrotoxicity Group (NG) - animals treated with the chemotherapeutic cisplatin (4mg/kg) and that did not receive MSC transplantation; and the Nephrotoxicity Group + Mesenchymal Stem Cell (NG + MSC) – animals treated with cisplatin and who received MSC transplantation (1,0 x 106 cells). The results demonstrated that the cellular therapy caused reduction of plasma levels of urea and creatinine. Histopathological analysis showed a reduction (p <0.05) in the frequency of NG + MSC damage in relation to NG. In view of the results presented, it is inferred that cell therapy with mesenchymal stem cells is a possibility of choice for the treatment of acute renal injury.